Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Receivables - NetReceivables - Other
Ratios

Marker Therapeutics (MRKR) Accumulated Depreciation & Amortization (2018 - 2023)

Marker Therapeutics (MRKR) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $3.3 million as the latest value for Q1 2022.

  • On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $3.3 million in Q1 2022 year-over-year; TTM through Mar 2022 was $3.3 million, a N/A change, with the full-year FY2020 number at $591264.0, up 460.59% from a year prior.
  • Accumulated Depreciation & Amortization was $3.3 million for Q1 2022 at Marker Therapeutics, up from $591264.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.3 million in Q1 2022 to a low of $332.0 in Q4 2018.
  • A 4-year average of $590646.6 and a median of $71119.0 in 2019 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 31668.67% in 2019, then surged 460.59% in 2020.
  • Marker Therapeutics' Accumulated Depreciation & Amortization stood at $332.0 in 2018, then soared by 31668.67% to $105472.0 in 2019, then soared by 460.59% to $591264.0 in 2020, then skyrocketed by 460.84% to $3.3 million in 2022.
  • Per Business Quant, the three most recent readings for MRKR's Accumulated Depreciation & Amortization are $3.3 million (Q1 2022), $591264.0 (Q4 2020), and $105472.0 (Q4 2019).